Company intelligence
Boston Institute of Biotechnology
CDMO | Biologics | Gene Therapy | Microbial | Mammalian | CMC | GMP
About Boston Institute of Biotechnology
As a Contract Development and Manufacturing Organization (CDMO), the Boston Institute of Biotechnology, LLC, provides full-spectrum services for microbial expression system, mammalian expression system, gene therapy and cell therapy. Boston BIB occupies a facility of 6,000 sf. that includes isolated laboratory spaces for cell culture, fermentation, purification and analytical services. Our facility in Southborough MA, within the Genetown Hotbed of Metro-Boston Area, offers flexible and adaptable lab spaces designed to meet the needs of our clients . Our mission is to be a trustable partner to our clients by delivering robust bioprocess solutions on time. BIB is dedicated to building up long-term strategic partnerships with the clients. We value the success of our clients as our success, and stand by our clients along with his way to the success. From DNA to clone selection and stability, BIB can provide strain and cell line development work based on the extensive industry experience with different types of mammalian cell lines, as well as several kinds of micro-organisms. Boston Institute of Biotechnology develops and runs reproducible, robust and scalable microbial fermentation and mammalian cell culture process for the production of therapeutic protein and antibodies. We have years of experience with fermentation and mammalian cell culture technologies to meet the future commercial requirement such as high throughput process development technologies, disposable mini bioreactors, high cell density screening, and complex system optimization.
Verified activity
Signals from Boston Institute of Biotechnology
2 published signals
Presence & Recognition
Boston Institute of Biotechnology is exhibiting its CDMO capabilities from 50L to 50,000L at the BPI conference in Boston from September 22-25, 2026.
Reported by Kyle Tibbert
People
Boston Institute of Biotechnology welcomed Dr. Axel Schleyer as its new Chief Business Officer (CBO) to strengthen BiBo and BIB's global presence.
Reported by Boston Institute of Biotechnology